Reply  by Mason, Peter J. et al.
Association guidelines give aspirin a class I indication for use in
patients with chronic stable angina (level of evidence A) (3). This
recommendation, however, has been interpreted to embrace a
myriad of aspirin formulations: various salts, polymer-coated in
rapid-release (compressed, soluble), buffered, and enteric-coated
preparations, which may influence the bioavailability of the prep-
aration (4). We recently evaluated the effect of low-dose enteric-
coated aspirin preparations on platelet COX-1 in both healthy
volunteers and patients with stable CAD. Low-dose enteric-coated
aspirin failed to inhibit platelet cyclooxygenase in some individuals.
Specifically younger, heavier patients and those with a history of
prior myocardial infarction were less likely to have an adequate
response (5).
Not withstanding the initial uncontrolled studies, we agree that
the jury is still out on the clinical relevance of aspirin resistance.
However, it is not an unreasonable goal that a drug has its intended
pharmacological effect. In the case of aspirin, near complete
inhibition of platelet cyclooxygenase is most likely to be achieved
with the correct preparation and dose.
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REPLY
We appreciate the comments and criticisms voiced by Dr. Maree
and colleagues. With respect to pharmacodynamic heterogeneity
and genotypic variation in cyclooxygenase (COX)-1, we applaud
the investigators’ work and agree that the single haplotype iden-
tified may contribute to, but not entirely explain, the phenomenon
of “aspirin resistance.” As suggested in our study (1), variation in
aspirin responsiveness is most likely explained by a combination of
several processes. If true, however, that 12% of the investigators’
cohort with stable coronary artery disease carried the specific
COX-1 haplotype, it may prove interesting to study this popula-
tion in greater detail. We also find interesting the observation by
Dr. Maree et al. that low-dose (75 mg) enteric-coated aspirin
failed to inhibit platelet COX in certain individuals. Although
previously studied in some detail, the effects of aspirin dose and
formulation are still worthy of further investigation. Finally, we
agree that the biological validity and clinical relevance of “aspirin
resistance” remains somewhat unproven.
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The Emperor’s New
Clothes Are Loose: Lower Body
Mass Index, Not Calorie Restriction,
Accounts for Improved Diastolic Function
A recent study in JACC (1) concludes that diastolic function is
improved in individuals on long-term calorie restriction (CR)
compared to those eating a “Western diet.” We would like to point
out that other studies demonstrate a correlation between diastolic
dysfunction and body mass index (BMI) as an independent factor.
In the study by Fontana et al. (1), control subjects eating a Western
diet had an average BMI of 27 kg/m2; the CR adherents had a
BMI of 19.7 kg/m2. Mortality and morbidity rise significantly
above a BMI of 22 kg/m2, and a BMI of 25 kg/m2 is (generously)
considered by U.S. Department of Agriculture panelists as the
upper limit of normal weight. Therefore, a BMI of 27 kg/m2 is
well within the category of overweight. An average male height 5
ft 9 inches with a BMI of 20 kg/m2 weighs 135 lbs. If his BMI is
27 kg/m2, he weighs 35% more at 182 lbs, a 47-lb difference!
In a study of the effect of isolated obesity on diastolic function
Pascual et al. (2), state: “Subclinical left ventricular diastolic
dysfunction is present in all grades of isolated obesity, correlates
with BMI, and is associated with increased systolic function in the
early stages of obesity.” In that study, a BMI between 25 and 29.9
kg/m2 was classed as “slight obesity.” Another study (3) states:
“Diastolic function was negatively correlated with age, BMI,
systolic blood pressure, diastolic blood pressure and left ventricular
mass index.”
In addition, control subjects had 26% body fat, and the CR
subjects had 9.3%. Obesity is known to raise tumor necrosis
factor-alpha and other pro-inflammatory cytokines (4). Long-term
inflammatory effects may change ventricular elasticity, but the
observed difference may be due more to the large difference in body
fat and BMI than to the CR versus Western diets. It is probable
that the difference in diastolic function attributed to CR is at least
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